US OptionsDetailed Quotes
HUMA250117C4500
- 0.70
- -0.04-5.41%
15min DelayClose Jan 3 16:00 ET
0.70High0.70Low
0.70Open0.74Pre Close2 Volume758 Open Interest4.50Strike Price140.00Turnover85.96%IV1.96%PremiumJan 17, 2025Expiry Date0.60Intrinsic Value100Multiplier12DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.8083Delta0.3344Gamma7.29Leverage Ratio-0.0093Theta0.0012Rho5.89Eff Leverage0.0026Vega
Humacyte Stock Discussion
FDA delay in approving Humacyte stemmed from national security concerns - developed in collaboration with the DoD. An undeniable strategic advantage for the U.S. military.
The fact that we have a +10 billion $ runway is just nice to know.
Fresenius, with its stake and rights in Humacyte, could face a bidding war from Baxter, which seeks to expand its hemodialysis portfolio. Both see Humacyte’s innovative vascular technology as key to dominating the dialysis market.
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits. GREED will make losr and get trapped.
5. Always remember shorts include dark pools.
6. Most importantly, DON’T BLAME ME for your losses. I already give watchlist and stock education. The ball is on you. I give you “watchlist” which means its on watch for me, not an open po...
$Humacyte (HUMA.US)$
No comment yet